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AbstrAct
Objective To explore barriers and facilitators to 
accessing postdiagnosis HIV care in five sub-Saharan 
African countries.
Methods In-depth interviews were conducted with 
77 people living with HIV (PLHIV) in pre-antiretroviral 
therapy care or not-yet-in care and 46 healthcare 
workers. Participants were purposely selected from health 
and demographic surveillance sites in Karonga (Malawi), 
Manicaland (Zimbabwe), uMkhanyakude (South Africa), 
Kisesa (Tanzania) and Rakai and Kyamulibwa (Uganda). 
Thematic content analysis was conducted, guided by the 
constructs of affordability, availability and acceptability 
of care.-
results Affordability: Transport and treatment costs 
were a barrier to HIV care, although some participants 
travelled to distant clinics to avoid being seen by 
people who knew them or for specific services. Broken 
equipment and drug stock-outs in local clinics could also 
necessitate travel to other facilities. Availability: Some 
facilities did not offer full HIV care, or only offered all 
services intermittently. PLHIV who frequently travelled 
complained that care was seldom available to them 
in places they visited. Acceptability: Severe pain or 
sickness was a key driver for accessing postdiagnosis 
care, whereas asymptomatic PLHIV often delayed 
care-seeking. A belief in witchcraft was a deterrent to 
accessing clinical care following diagnosis. Changing 
antiretroviral therapy guidelines generated uncertainty 
among PLHIV about when to start treatment and delayed 
postdiagnosis care. PLHIV reported that healthcare 
workers’ knowledge, attitudes and behaviours, and 
their ability to impart health education, also influenced 
whether they accessed HIV care.
conclusion Despite efforts to decentralise services 
over the past decade, many barriers to accessing HIV 
care persist. There is a need to increase sustained access 
to care for PLHIV not yet on treatment, with initiatives 
that encompass biomedical aspects of care alongside 
considerations for individual and collective challenges 
they faced. A failure to do so may undermine efforts to 
achieve universal access to antiretroviral therapy.
IntrOductIOn
Writing in 2007, Anita Hardon and colleagues1 
observed that people living with HIV (PLHIV) in 
their study areas in Botswana, Tanzania and Uganda 
faced a number of barriers gaining access to HIV 
care and antiretroviral therapy (ART). They listed 
such constraints as ‘transport costs, user fees, long 
waiting times, hunger, stigma, side-effects, lack of 
appropriate counselling and workloads’ (p. 660). 
In the introduction to their seminal paper, Hardon 
et al remind us of the July 2005 goal set by the 
G8 meeting at the Gleneagles Summit to provide 
‘as close as possible’ universal access to ART to all 
those in need by 2010.2 In the decade since the 
publication of Hardon’s paper, barriers to accessing 
HIV care and ART persist, despite notable strides 
being made towards achieving this universal access 
goal, with improved availability of testing and treat-
ment in many African countries. In particular, many 
PLHIV who are asymptomatic are not entering care 
after receiving an HIV diagnosis.3 As discussed in 
the editorial of this volume,4 changes in treatment 
guidelines pose a challenge to the goal of achieving 
wider access to HIV care. As more people become 
eligible for ART, health systems struggle to keep 
up with demand.3 5–7 Yet, while shortages of staff 
or drugs may affect access for those who reach 
health services, additional obstacles continue to 
undermine that very access itself. In a systematic 
review focusing on retention in care between HIV 
testing and treatment access, Rosen and Fox8 note 
that there are ‘substantial’ losses from pre-ART 
care partly because people may not come back to 
clinic to collect ART, despite being eligible. With 
Key messages
 ► Factors influencing access to preantiretroviral 
therapy and care can be grouped into those 
relating to affordability, availability and 
accessibility.
 ► Most barriers to accessing HIV care in 
sub-Saharan Africa have persisted over the 
course of the past decade, despite initiatives to 
increase service provision.
 ► Interventions are needed to promote access 
to postdiagnosis HIV care that encompass 
biomedical aspects of care alongside 
considerations for individual and collective 
challenges faced by people living with HIV 
(PLHIV).
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table 1 Number of participants per study site and participant category
category
Karonga,
Malawi
Kisesa,
tanzania
Kyamulibwa,
uganda
rakai,
uganda
uMkhanyakude,
south Africa
Manicaland,
Zimbabwe total
Diagnosed no ART 9 13 8 15 16 16 77
No contact with care/ineligible 5 4 4 5 10 6 39
Eligible/pre-ART 4 9 4 10 6 10 38
Healthcare workers 5 7 5 6 19 4 46
Total 14 20 13 21 35 20 123
ART, antiretroviral therapy.
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this in mind, in this paper, we investigate the extent to which 
the barriers to linkage to care identified by Hardon et al1 are 
still present. An understanding of access barriers is crucial given 
global health priorities to expand to universal access to ART.
Drawing on data from five countries, and using a ‘frame-
work of access’ developed by McIntyre et al9 to evaluate general 
healthcare access and applied by Cleary et al10 in the context of 
access to ART, we group and expand on the barriers to access 
identified by Hardon et al. McIntyre’s framework provides a 
structure through which to assess the affordability, availability 
and acceptability of services. As Cleary et al explain (p.142), 
‘affordability’ is the fit between the costs of utilising a service 
and the patient’s ability to pay associated costs; ‘availability’ is 
the fit between a patient’s needs and type, place and time of 
services provided; and ‘acceptability’ is the fit between health-
care provider and patient attitudes and expectations of each 
other.
MethOds
study setting
Data for this paper were drawn from the Bottlenecks Study4 
covering six health and demographic surveillance sites across 
five countries in Eastern and Southern Africa within the ALPHA 
network (http:// alpha. lshtm. ac. uk/). More information can be 
found in the online methods supplement found at http:// dx. 
doi. org/ 10. 1136/ sextrans- 2017- 053172.11 The study sites were: 
Karonga (Malawi), Manicaland (Zimbabwe), uMkhanyakude 
(South Africa), Kisesa (Tanzania), and Rakai and Kyamulibwa 
(Uganda). In the five countries, national policies are in place 
to provide free HIV testing through a variety of models and 
those diagnosed HIV-positive are referred for care to a govern-
ment-run clinic, except for Kyamulibwa where referral is to 
either a government or non- governmental clinic. All but one 
(Karonga) of the surveillance sites have the capacity to follow 
individuals from diagnosis through care initiation and monitor 
subsequent HIV care engagement.
sampling frame and participants
PLHIV were purposively sampled to include those who had 
enrolled in pre-ART care (accessing co-trimoxazole) and those 
tested but not yet enrolled into care. Only in the Kyamulibwa 
site were PLHIV in pre-ART care randomly sampled due to large 
numbers. In the rest of the sites, PLHIV and in all sites, health-
care workers (HCWs) (eg, nurses and medical assistants) were 
purposively recruited into the study.
data collection, management and analysis
Data were generated through face-to-face in-depth interviews 
(IDIs), conducted by trained social science interviewers. The 
interviews were held in the participants’ homes/places of work/
other venues of their choice and lasted between 60 and 90 min. 
IDIs with PLHIV covered the individual circumstances influ-
encing HIV testing uptake, enrolment and retention in pre-ART 
HIV care. IDIs with HCWs focused on their experiences of 
offering HIV care and circumstances affecting people’s enrol-
ment into care. All IDIs were audio-recorded. Detailed interview 
summaries with illustrative quotations were developed at the 
Kyamulibwa site and analysed manually. In other sites, audio-re-
corded interviews were transcribed and translated into English 
before importing into Nvivo V.8/10. All data were coded and 
analysed thematically, using deductive and inductive logic by 
teams at each site. The site lead researchers produced detailed 
analytical summaries from emerging themes and subthemes 
from the analysis. The lead author reviewed the summaries and 
developed an analytical coding scheme based on elements of the 
access framework described above. There were regular discus-
sions with in-country study coordinators to ensure emerging 
findings agreed with data interpretation.
ethical considerations
The study received ethics approval in each of the participating 
countries and from the ethics committee at London School 
Hygiene and Tropical Medicine. Prior to data collection partic-
ipants were provided with an information sheet on what the 
study was about and opportunities to ask questions. All partici-
pants gave written informed consent.
results
A total of 123 people participated in the study (77 PLHIV and 
46 HCWs, see table 1).
Affordability
Both patients and HCWs reported transport cost as a major 
barrier to access free HIV services in all study sites, except 
Zimbabwe, compounded in some places (Malawi, Tanzania and 
Uganda) by the distance that had to be travelled for services 
where free treatment was available.
The government health facilities are located far. You need to spend 
about 20,000/= ($5-$6) on a return journey. […] you cannot 
get affordable services around here. (Female, PLHIV on Pre-ART, 
Uganda)
In Zimbabwe, it was reported that HIV service decentralisa-
tion had removed this access barrier. In other places, outreach 
clinics had made services more accessible for some by offering 
pre-ART testing, health education and co-trimoxazole/Bactrim 
drug refills. Participants in Tanzania and Uganda recalled a time 
when transport had usefully been provided for those in serious 
need, and home visits for follow-up made, but funding cuts had 
since affected that provision.
Yet at all sites, HIV stigma influenced the distance travelled for 
testing and postdiagnosis care. Some people preferred to travel 
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to distant places to avoid being seen by people who knew them. 
Additional costs were incurred if these more distant facilities 
were private clinics. In all the sites, participants mentioned that 
securing funds for both the trip and the private service could 
delay access to care.
Others had to travel for specific services. Pregnant women in 
Kyamulibwa, Uganda, for example, had to access Option B+ 
at more distant public facilities because the local clinic did not 
provide antenatal care. In Malawi and Zimbabwe, CD4 testing 
pre-ART sometimes had to be sought from distant facilities 
because of faulty testing machines at the local clinic.
They said you should take your medication on time and constantly 
get CD4 count. However, the machine for the CD4 count is not 
working at this clinic.[…] I came here last month and heard that the 
machine was down and you should go [elsewhere]. (Female, PLHIV-
diagnosed, not in care, Zimbabwe)
In addition to broken equipment, drug stock-outs in local 
clinics could also necessitate travel to more distant facilities, 
which may make the service unaffordable and therefore unavail-
able. Next, we explore availability further.
Availability
In all but one site (Rakai, Uganda), PLHIV reported that access to 
pre-ART care services was delayed or unsuccessful because some 
health facilities did not offer all the HIV care components, or 
offered them intermittently. Some facilities in Malawi, Tanzania 
and Zimbabwe lacked CD4 testing machines (or, as noted above, 
the machine was broken).
We don’t test for the CD4 here but after referring them to xxx we 
just follow him to find out if he went, so if someone went to xxx we 
ask him to give us what was recorded. (HCW, Malawi)
Interestingly, some delays in access to care were attributed 
by respondents not to the lack of services, but to the lack of 
follow-up from HCWs to get PLHIV into care. However, in most 
of the sites, some provision for follow-up was offered. PLHIV 
were actively followed up in some cases through home visits and/
or SMS messaging and outreach services. However, in most sites, 
follow-up had reduced in recent years because of funding cuts.
Availability of services was also affected by the mobility of 
PLHIV, particularly in Malawi, Tanzania and both Kyamulibwa 
and Rakai in Uganda where many people travelled for work. 
PLHIV explained that clinics in the surveillance sites targeted 
specific catchment areas and when moving to areas outside the 
surveillance site, they became ineligible to be served by those 
clinics, with potential interruptions in care. PLHIV explained 
that these interruptions happened because they could not get 
refills of their pre-ART drug (co-trimoxazole/Bactrim). They 
also frequently complained that if they tried to go to a clinic in 
the area they were visiting, they would have to start the process 
of testing and assessment afresh to get the service they wanted. 
The inaccessibility of postdiagnosis services to visiting non-res-
idents of clinic catchment areas was also reported by HCWs, 
although sometimes HCWs did help visiting PLHIV.
I had gone to nurse my late mother with my drugs and they got 
finished while I was still in xxx. I decided to go in xxx referral 
hospital with my treatment cards [from local clinic] and showed 
them to the nurses. I told them that I was getting the drugs 
from xxx and that they were now remaining only three tablets. 
They gave me drugs for one month and when I came back here, 
I went to [the clinic] and reported it then I was given drugs for 
one month and given another appointment. (Female, PLHIV pre-
ART, Uganda)
The availability issues above highlight leakages in the HIV 
care continuum at every stage: linking to care, starting ART 
and sustaining ART access. Gaining and maintaining access 
to ART also depend on the acceptability of the services avail-
able.
Acceptability
In Malawi, Uganda and Zimbabwe, many PLHIV and HCWs 
reported that having severe pain/sickness was one of the main 
motivators for seeking postdiagnosis care. Those who were 
asymptomatic saw little reason to seek care.
I was not sick during that time; my body was just healthy. Even 
though I tested positive my body was just healthy and I didn’t also 
suffer from any sickness. (Female, PLHIV- on Pre- ART, Malawi)
PLHIV and HCWs in Malawi, South Africa and Uganda 
reported that a belief in witchcraft was a major deterrent to 
accessing postdiagnosis care because health conditions linked 
to witchcraft required traditional healing. Therefore, the treat-
ment offered at clinics was not acceptable and indeed, for some 
people, using a drug from a clinic to treat a traditional disease 
could impede recovery.
Beliefs about witchcraft could be reinforced by family and 
friends.
I had these swellings in the neck and he (brother) would tell me 
that you probably ate some things that were stolen. And yet I had 
never stolen anything in my life. So I was really confused, some 
people would say that I was possessed by a local god and it used 
to just confuse me all the more. That day I was going to a different 
traditional doctor when they told me that I have the virus and that is 
what was making me sick. (Male, PLHIV pre-ART, Uganda)
Some HCWs in South Africa and Uganda reported recognising 
the benefits of the updated ART guidelines, but to some extent 
found the changes confusing and difficult to justify to patients. 
This generated uncertainty among their patients about when 
to start treatment, which contributed to delays in HIV postdi-
agnosis care. HCWs advocated for more resources to provide 
accurate information on what is available in terms of HIV care 
and for whom. HCWs further noted that some PLHIV needed 
more time than others to come to terms with their HIV status 
prior to accepting HIV treatment and may thus wish to postpone 
treatment initiation.
Counselling must be deep so that it will last for a long time in a 
patient’s mind, and that way they can’t drop out of pre-ART services 
or treatment. […] The kind of patients that are not ready are those 
who hold on to things like’ X infected me’ or ‘Y told me to nurse her 
sick child’! […] The ready patients are those that accept their status 
and forget about ‘who stole whose man’, and so forth and take the 
treatment. (HCW, South Africa)
While PLHIV and HCWs reported well-managed and coor-
dinated HIV care services at the surveillance site clinics, with 
good records on those accessing services (including pre-HIV 
and post-HIV counselling), some considered ‘too much moni-
toring’ an obstacle to sustained attendance. For example, there 
were concerns that insisting on short times between refills of 
drugs affected the acceptability of care. This was echoed by some 
HCWs.
The major challenge among new cases is that we give them short 
periods to return. […] So you have seen a client who’s new, he even 
still fears coming to the clinic because it’s for positive people but 
they have to come back for bleeding […] ‘frequent visits’ […] can 
challenge them because most people come from far. (HCW, Uganda)
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Figure 1 Evolution of International Goals and ART Access Targets and barriers to ART access. 
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However, it was also the case that short intervals between 
drug refills were sometimes due to HCWs managing a shortage 
in drug supplies. HCWs also noted that some people appreciated 
short gaps between clinic visits if they needed encouragement to 
take their treatment.
Across the sites, PLHIV reported that the quality of HCWs’ 
knowledge and their ability to impart health education influ-
enced the acceptability of care. Matters were not helped by 
counsellors’ explanations that participants could not under-
stand (sero-discordance, and different guidelines for pregnant 
women and general population were mentioned), which made 
them doubt the competence of the clinic staff overall. Dissatis-
faction with health education or counselling was also reported in 
Malawi, Tanzania, and Kyamulibwa, in Uganda.
HCWs’ behaviour also impacted on acceptability in Malawi, 
South Africa, Tanzania and Uganda. Some HCWs were reported 
to be rude, which frightened patients away. Furthermore, 
breaches in confidentiality, with HCWs disclosing who had 
tested HIV positive and who had been initiated onto treatment, 
put PLHIV off attending services.
Some doctors or nurses should go for further training in order 
to learn how to handle patients especially those with AIDS. […] 
patients need much care and not to be harassed or shouted at. 
(Female, PLHIV not in care, Uganda)
However, the acceptability of care was enhanced whenever 
support was available. PLHIV in all the study sites reported that 
they appreciated receiving psychological support to encourage 
testing and engagement in care and/or economic support.
After they counselled me, I was encouraged to go to the xxx and start 
medicine. I have now realised that the counselling that I was given 
was beneficial to me (Male, PLHIV pre-ART, Malawi)
Material, as well as psychological, support often came from 
relatives and friends but also from HCWs who occasionally 
helped patients they felt were in need.
Some PLHIV, in all sites, associated being unmarried and 
living alone with a lack of support and encouragement, which 
they reported as a main cause of their delayed access to pre-ART 
care. However, interestingly, some participants in Tanzania said 
that being single had motivated them to seek healthcare, because 
they knew they would have no one to help them if they were to 
become very ill. And, in many sites, married PLHIV mentioned 
that unsupportive partners delayed their access to care.
I only got support from the counsellor but there was no support 
from the partner. (Female, PLHIV-on ART, Uganda)
Where peer groups of PLHIV existed, these were not always 
considered supportive. In Malawi, newly diagnosed PLHIV 
commented that it was hard to join existing groups, and some 
PLHIV in South Africa said that they had lost enthusiasm for 
support groups over time.
The acceptability of treatment affected access to care among 
those diagnosed with HIV. A change in service provision (eg, a 
less supportive health worker or change in clinic services) could 
render ART access less acceptable, even if it were both affordable 
and available.
dIscussIOn
The reasons given by PLHIV in our study for not accessing 
postdiagnosis care echo the earlier findings of Hardon et al1 
(see figure 1). Despite increased decentralisation of treatment, 
distance, equipment breakdown and transport costs still matter, 
with revisions to guidelines increasing the number of people 
eligible for treatment. Stigma and fears over the personal and 
familial consequences of starting on treatment also remain 
important, as demonstrated in other settings.12–15
Moreover, our findings suggest that the interaction between 
these barriers may be more important than the singular role 
played by each factor. The affordability and availability of 
services interact in complex ways and are affected by the 
acceptability of care across contexts. If someone fears being seen 
at their local clinic, for example, that care is unacceptable and 
unavailable, perhaps resulting in an unaffordable cost to them 
seeking care elsewhere.
As the findings of the ANRS 12249 TasP Trial have shown,16 
innovative approaches of linking people to care are needed, if 
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universal ‘test and treat’ is to succeed. Much can be learnt from 
demographic surveillance studies that will be relevant to health-
care systems in general. Healthcare systems in similar resource-
poor settings should strengthen linkages with social services, 
and HCWs should be trained to recognise and address social 
and economic concerns faced by PLHIV. Furthermore, demon-
strating patient-centredness in the services provided to PLHIV 
would improve quality of care in the health services. Initiatives 
that aim to integrate HIV care with other services17 may provide 
a way forward in tackling some of these barriers to entry and 
retention in postdiagnosis care.
cOnclusIOn
There is a need to increase access to and retention in HIV care 
for PLHIV, with initiatives that focus on biomedical aspects 
of HIV care, such as monitoring the CD4 count or viral load, 
and that consider individual and collective challenges faced by 
PLHIV. As calls for ‘test and start’ increase, growing numbers 
of asymptomatic PLHIV will require tailored support and care, 
alongside an assured drug supply.
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